|
Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19
|
24 March 2022 |
|
New Vaxzevria data further support its use as third dose booster
|
13 January 2022 |
|
AstraZeneca and Ionis close agreement to develop and commercialise eplontersen
|
30 December 2021 |
|
Vaxzevria significantly boosted antibody levels against Omicron
|
23 December 2021 |
|
Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study
|
17 December 2021 |
|
Two billion doses of AstraZeneca’s COVID-19 vaccine supplied to countries across the world
|
16 November 2021 |
|
AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US
|
05 October 2021 |
|
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
|
20 August 2021 |
|
Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people
|
28 July 2021 |
|
AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity
|
27 July 2021 |